Navigation Links
Elsevier Introduces Article-Based Publishing to Increase Publication Speed
Date:10/6/2010

src='http://server.iad.liveperson.net/hc/23818417/?cmd=repstate&site=23818417&&ver=1&imageUrl=http://content.prnewswire.com/designimages&skill=PRN' id="chatimage" border="0" style="display:none;" > --> Publishing & Information Services, Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, New Products & Services Click to view news release full screen  

Elsevier Introduces Article-Based Publishing to Increase Publication Speed

 

AMSTERDAM, October 6, 2010 /PRNewswire-FirstCall/ --

- Final and Citable Articles are Published Without Needing to Wait Until a Journal Issue is Complete; Speeding the Publication Process by an Average of 7 Weeks

Elsevier, the world-leading publisher of scientific, technical and medical information products and solutions, announced today the launch of Article-Based Publishing -- a new publishing model that publishes articles as final and citable without needing to wait until a journal issue is complete. With an increa
'/>"/>

SOURCE Elsevier
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Elseviers PharmaPendium(TM) Adds European Medicines Agency (EMEA) Documents
2. Elsevier and the Association of Southeast Asian Institutions
3. Elseviers EMBASE.com Partners With QUOSA
4. Elsevier Announces Winners of 3rd Annual Scopus Young Indian Scientist Award
5. Elsevier Introduces The American Journal of Medicine Blog
6. Elsevier Introduces Breakthrough Technology Intelligence Solution for Accelerating R&D and Innovation in Europe
7. The American Medical Association and Elsevier Join to Co-Publish ICD-9-CM and HCPCS Coding Reference Books
8. Elsevier and Brain Mapping Foundation Co-Host 6th Annual World Congress of IBMISPS on Brain Mapping and Image Guided Therapy
9. Elsevier Launches Ten New eBook Specialty Collections on MD Consult
10. Elsevier Health Sciences Appoints Dr. David Goldmann Editor-in-Chief of its First Consult Point of Care Resource
11. Statement From Michael Hansen, CEO of Elseviers Health Sciences Division, Regarding Australia Based Sponsored Journal Practices Between 2000 and 2005
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... ST. LOUIS , Dec. 23, 2014 /PRNewswire/ ... announced today that the waiting period under the ... with the acquisition expired on December 22, 2014, ... and review requirement for the acquisition of the ... U.S. antitrust clearance satisfies another condition to ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 ... pilot study of mazindol in children with attention deficit/hyperactivity ... in December 2014 . The paper, ... with attention deficit/hyperactivity disorder" ( Konofal et al, ... 1;8:2321-2332. eCollection 2014 ) shows that mazindol might ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
(Date:12/22/2014)... 2014  Alternative Energy & Environmental Solutions, Inc., ... a letter of intent to acquire BioTechPharma Corporation, ... a nanotechnology-based development platform used to create drug ... on-site collection and testing to identify infectious disease, ... an immediate, non-invasive and cost-effective manner. ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2
... Friday announced the availability of RFID 360, a ... major retailer and Department of Defense compliance. RFID 360 ... RFID implementation environment and schedule. , ,The first software ... others, is RFID Data Manager. Data Manager is designed ...
... engine company, set the business world abuzz with the ... so it released data about its financial performance that ... analysts however, criticized the company and its founders for ... proposed for its stock offering. While some trepidation is ...
... Note: The Wisconsin Technology Network is committed to ... and deployment of technology. We salute the administration and ... help spread the adoption health technology. If you ... should attend the following event. , ,The ...
Cached Biology Technology:RedPrairie announces RFID 360 compliance software 2Why Google Matters 2Why Google Matters 3The doctor is in: Thompson prescribes better health information technology 2The doctor is in: Thompson prescribes better health information technology 3The doctor is in: Thompson prescribes better health information technology 4
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
(Date:12/10/2014)... DUBLIN , Dec. 08, 2014 Research ... announced the addition of the "Biometrics Market ... http://photos.prnewswire.com/prnh/20130307/600769 ... for projects such as rural banking and upgradation ... major trends witnessed in the market. Besides the ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... of chromosomes, and even a small change in this structure ... can lead to severe physical impairment. So it,s no ... frequently a contributing factor, says Prof. Ron Shamir of the ... Now Prof. Shamir and his former doctoral students Michal Ozery-Flato ...
... release is available in Spanish . ... because of their characteristics, produce a certain amount of social ... fact that they are subjected to moral conflicts and ethical ... very necessary from a social perspective, as in the case ...
... Institute scientist Matthias von Herrath, M.D., a world leader in ... seeing his discoveries translated into new therapies to better treat ... may soon get his chance as head of a new ... in 2012 by Novo Nordisk, a global healthcare company specializing ...
Cached Biology News:Patterns of chromosome abnormality: The key to cancer? 2Moral imagination as a key to overcoming work-related stigmas 2La Jolla Institute scientist takes quest to conquer Type 1 diabetes to the next level 2
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... Rabbit polyclonal to ErbB 2 - ... for all tested applications). ... AENPEYLGLDVPV conjugated to KLH, corresponding to ... Human c-ErbB2 Entrez ...
Anti human PPAR gamma2 mouse monoclonal antibody...
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
Biology Products: